癌胚蛋白HLF反式激活c-Jun促进肝细胞癌发生发展及索拉非尼耐药
本研究评估了肝白血病因子(HLF)在胎儿肝脏、成人肝脏及肝细胞癌(HCC)组织中的表达,在体内外探究HLF对HCC发生和进展的影响,并在患者队列及人源异种移植瘤(PDX)中分析HLF与预后及索拉非尼疗效的相关性。结果发现HLF是一种由SOX2和OCT4在HCC中重新激活的新癌胚蛋白,通过反式激活c-Jun促进肿瘤起始细胞生成,驱动HCC发生发展并决定索拉非尼反应,HLF/c-Jun轴可能作为索拉非尼获益的生物标志物。
要点
- HLF是由SOX2和OCT4在HCC中重新激活的新型癌胚蛋白。
- HLF反式激活c-Jun促进肿瘤起始细胞生成并驱动HCC进展。
- HLF/c-Jun轴可决定索拉非尼反应,干扰HLF增强索拉非尼疗效。
核心结论
- HLF是一种新型癌胚蛋白,HLF/c-Jun轴在HCC发生发展和索拉非尼反应中起关键作用,使HLF成为HCC预防和干预的理想靶点。
研究设计与样本
- 采用胎儿肝脏、成人肝脏和HCC组织评估HLF表达。
- 在体内和体外研究HLF对HCC发生和进展的影响。
- 在患者队列中确定HLF与预后的关联,并在患者队列和PDX中评估HLF表达与索拉非尼获益的相关性。
主要发现
- HLF是由SOX2和OCT4在HCC中重新激活的新型癌胚蛋白。
- HLF反式激活c-Jun促进肿瘤起始细胞生成并增强肝癌细胞的肿瘤起始细胞样特性,从而驱动HCC发生和进展。
- 临床研究阐明了HLF与患者预后的关联,并揭示了患者HCC中HLF水平与c-Jun表达的密切相关性。
- HLF/c-Jun轴决定肝癌细胞对索拉非尼治疗的反应,干扰HLF可消除c-Jun激活并增强索拉非尼反应。
- 患者队列和PDX分析提示HLF/c-Jun轴可能作为HCC患者索拉非尼获益的生物标志物。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: The unique expression pattern makes oncofetal proteins ideal diagnostic biomarkers and therapeutic targets in cancer. However, few oncofetal proteins have been identified and entered clinical practice. METHODS: Fetal liver, adult liver and hepatocellular carcinoma (HCC) tissues were employed to assess the expression of hepatic leukaemia factor (HLF). The impact of HLF on HCC onset and progression was investigated both in vivo and in vitro. The association between HLF and patient prognosis was determined in patient cohorts. The correlation between HLF expression and sorafenib benefits in HCC was further evaluated in patient cohorts and patient-derived xenografts (PDXs). RESULTS: HLF is a novel oncofetal protein which is reactivated in HCC by SOX2 and OCT4. Functional studies revealed that HLF transactivates c-Jun to promote tumour initiating cell (TIC) generation and enhances TIC-like properties of hepatoma cells, thus driving HCC initiation and progression. Consistently, our clinical investigations elucidated the association between HLF and patient prognosis and unravelled the close correlation between HLF levels and c-Jun expression in patient HCCs. Importantly, HLF/c-Jun axis determines the responses of hepatoma cells to sorafenib treatment, and interference of HLF abrogated c-Jun activation and enhanced sorafenib response. Analysis of patient cohorts and PDXs further suggests that HLF/c-Jun axis might serve as a biomarker for sorafenib benefits in HCC patients. CONCLUSIONS: Our findings uncovered HLF as a novel oncofetal protein and revealed the crucial role of the HLF/c-Jun axis in HCC development and sorafenib response, rendering HLF as an optimal target for the prevention and intervention of HCC.
引用
- Xiang DM, Sun W, Zhou T, et al. Oncofetal HLF transactivates c-Jun to promote hepatocellular carcinoma development and sorafenib resistance. Gut. 2019. PMID: 31118247. doi:10.1136/gutjnl-2018-317440
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。